Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: April 29, 2024
Context: The filing serves as a Regulation FD disclosure to provide a slide presentation reviewed during the company's program update call and webcast regarding its CAP-1002 Duchenne muscular dystrophy (DMD) program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of non-financial program updates and does not contain audited or unaudited financial statements.
Material Changes
No material financial changes versus prior periods are reported in this filing. The primary event is the dissemination of clinical program information for CAP-1002.
Guidance, Outlook, and Risks
- Program Update: The company provided an update on its CAP-1002 program for Duchenne muscular dystrophy (DMD).
- Legal Status of Information: The information furnished in this report and the attached Exhibit 99.1 (slide presentation) is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
- Incorporation by Reference: The content shall not be incorporated by reference into any of the Company's filings under the Exchange Act unless expressly set forth as being incorporated.
Investor Verification Checklist
- Verify the specific clinical data and trial results presented in the attached Exhibit 99.1 slide presentation, as the 8-K text only references the existence of the presentation.
- Confirm the date and time of the webcast associated with the CAP-1002 program update.
- Review subsequent filings (e.g., 10-Q or 10-K) for any financial impact resulting from the clinical program updates discussed.